비교리스트

 카트 문의
시장보고서
상품코드
1446479

원료의약품 CDMO 시장 - 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 합성별, 약제별, 용도별, 워크플로우별, 지역별, 부문별 예측(2024-2030년)

Active Pharmaceutical Ingredient CDMO Market Size, Share & Trends Analysis Report By Product, By Synthesis, By Drug, By Application, By Workflow, By Region, And Segment Forecasts, 2024 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 137 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

원료의약품 CDMO 시장의 성장 및 동향 :

세계의 원료의약품 CDMO 시장 규모는 2030년에 1,645억 달러에 달할 전망이며, 2024년부터 2030년에 걸쳐 CAGR 7.4%로 성장할 것으로 예측됩니다.

의약품 R&D 투자 증가, 특허 만료, 제네릭 의약품 및 생물학적 혁신에 대한 수요 증가가 아웃소싱의 촉진요인이 되고 있습니다.

저분자 의약품 증가, 원약(API)의 복잡화, 비용 절감의 필요성이 의약품 분야에서 아웃소싱 서비스의 급속한 확대에 기여하고 있습니다. 개발 및 제조 수탁기관(CDMO) 분야에서 세계의 리치와 규모를 획득하고 있는 기업은 작고 아직 단편적입니다. 또한 많은 기업들이 원료 및 제제의 통합 소스로 원스톱 숍 솔루션을 제공합니다.

의료 업계는 역동적인 변화 과정에 있으며, 급속한 기술 진보(자동화나 AI 등), CRO, CMO 및 CDMO의 필요성, 연구 투자 증가 등의 요인이 의료 시장에 영향을 주고 있습니다. 활동 아웃소싱은 비즈니스 효율성 개선, 지리적 존재 확대, 자원 비용 절감, 치료 전문 지식 획득, 온디맨드 서비스 강화 등 많은 제약 회사에 이익을 제공합니다.

COVID-19의 팬데믹은 인공 호흡 중 중증 환자를 관리하는 데 필요한 의약품에 대한 수요가 크게 증가했기 때문에 분명히 알 수 있듯이 의약품 제조업체에 전례없는 기대를 걸었습니다. 그 결과, 급격한 증산이 필요하게 되었기 때문에 원료의약품 CDMO에는 의약품 공급을 유지하기 위한 적응력을 요구하게 되었습니다. 세계의 새로운 치료에 대한 수요 증가 및 팬데믹 후 임상 연구 증가가 앞으로 수년간 시장을 지원할 것으로 예상됩니다.

원료의약품 CDMO 시장 보고서 하이라이트

  • 전통적인 의약품 부문은 시장을 독점했으며 2022년에는 39.8%의 최대 수익 점유율을 차지했습니다.
  • 혁신적인 의약품 부문은 2022년에 73.7%의 수익 점유율을 차지했습니다. 이는 주로 신규분자체에 대한 FDA 승인 증가, 혁신적인 API 기업에 의한 연구개발에 대한 주력 증가로 인한 것입니다.
  • 종양 분야는 2022년에 35.5%의 최고 매출 점유율로 시장을 선도했습니다. 이는 암 치료용 고활성 API에 대한 수요가 증가하고 있기 때문입니다.
  • 바이오 분야는 만성 질환이나 감염증의 치료에 바이오 의약품이 많이 채용되고 있기 때문에 예측 기간 중에 7.0%의 가장 빠른 성장이 전망되고 있습니다.
  • 임상 워크플로우 분야는 예측 기간에 가장 빠른 CAGR 7.3%가 예상됩니다. 원료 수요를 지원하는 임상 연구 건수 증가가 이 분야의 성장을 가속하는 주요 요인 중 하나입니다.
  • 아시아태평양에서는 예측 기간 동안 가장 빠른 CAGR 9.1%를 기록할 전망입니다. 인도나 중국 등의 개발도상국에서는 제약회사나 제조수탁기관의 수가 급증하고 있기 때문에 이 지역은 가까운 미래에 유럽이나 북미를 추월할 가능성이 높습니다.

목차

제1장 원료의약품 CDMO 시장 : 조사 방법 및 범위

제2장 원료의약품 CDMO 시장 : 주요 요약

  • 시장 현황
  • 제품 및 합성의 스냅샷
  • 의약품 및 용도의 스냅샷
  • 워크플로우의 스냅샷
  • 경쟁 구도의 스냅샷

제3장 원료의약품 CDMO 시장 : 변수, 동향 및 범위

  • 시장 세분화 및 범위
  • 시장 계통 전망
  • 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
  • 원료의약품 CDMO 시장 분석 툴

제4장 원료의약품 CDMO 시장 : 제품별 추정 및 동향 분석

  • 제품별 시장 점유율(2023년, 2030년)
  • 부문 대시보드
  • 세계의 원료의약품 CDMO 시장 : 제품별 전망
  • 시장 규모, 예측 및 동향 분석(2018-2030년)

제5장 원료의약품 CDMO 시장 : 합성별 추정 및 동향 분석

  • 합성별 시장 점유율(2023년, 2030년)
  • 부문 대시보드
  • 세계의 원료의약품 CDMO 시장 : 합성뵬 전망
  • 시장 규모, 예측 및 동향 분석(2018-2030년)

제6장 원료의약품 CDMO 시장 : 약제별 추정 및 동향 분석

  • 약제별 시장 점유율(2023년, 2030년)
  • 부문 대시보드
  • 세계의 원료의약품 CDMO 시장 : 약제별 전망
  • 시장 규모, 예측 및 동향 분석(2018-2030년)

제7장 원료의약품 CDMO 시장 : 용도별 추정 및 동향 분석

  • 용도별 시장 점유율(2023년, 2030년)
  • 부문 대시보드
  • 세계의 원료의약품 CDMO 시장 : 용도별 전망
  • 시장 규모, 예측 및 동향 분석(2018-2030년)

제8장 원료의약품 CDMO 시장 : 워크플로우별 추정 및 동향 분석

  • 워크플로우별 시장 점유율(2023년, 2030년)
  • 부문 대시보드
  • 세계의 원료의약품 CDMO 시장 : 워크플로우별 전망
  • 시장 규모, 예측 및 동향 분석(2018-2030년)

제9장 원료의약품 CDMO 시장 : 지역별 비즈니스 분석

  • 지역별 시장 점유율 분석(2023년, 2030년)
  • 지역별 시장 대시보드
  • 세계 지역 시장 현황
  • 시장 규모, 예측 및 동향 분석(2018-2030년)
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카

제10장 경쟁 구도

  • 주요 시장 진출기업별 최근의 동향 및 영향 분석
  • 회사 및 경쟁의 분류
  • 벤더 상황
    • List Of Key Distributors And Channel Partners
    • Key Customers
    • Key Company Market Share Analysis, 2023
    • Cambrex Corporation
    • Recipharm CP
    • Thermo Fisher Scientific Inc.(Pantheon)
    • CordenPharma International
    • Samsung Biologics
    • Lonza
    • Catalent, Inc.
    • Siegfried Holding AG
    • Piramal Pharma Solutions
    • Boehringer Ingelheim International GmbH
AJY 24.03.21

Active Pharmaceutical Ingredient CDMO Market Growth & Trends:

The global active pharmaceutical ingredient CDMO market size was valued at USD 164.5 billion in 2030 and is projected to grow at a compound annual growth rate (CAGR) of 7.4% from 2024 to 2030. Increasing pharmaceutical R&D investments, patent expirations, and a rise in demand for generic drugs and biologic innovations propelling outsourcing are the factors driving the market.

The growth of small molecules, rising active pharmaceutical ingredient (API) complexity and the need to reduce costs are factors contributing to the rapid expansion of outsourcing services in the pharmaceutical sector. Only a few companies have achieved global reach and scale in the contract development and manufacturing organization (CDMO) sector, which is still fragmented. Besides, many companies are providing one-stop-shop solutions as an integrated source of APIs and formulations.

As the healthcare industry is undergoing a process of dynamic change, factors such as rapid technological advancements (e.g., automation & AI), the need for CROs/CMOs/CDMOs, and rising investments in research are influencing the healthcare market. The outsourcing of activities is benefitting many pharmaceutical companies in improving their operational efficiencies, expanding their geographical presence, decreasing resource costs, gaining therapeutic expertise, and enhancing on-demand services.

The COVID-19 pandemic placed unprecedented expectations on API makers, as evidenced by the substantial increase in demand for medications required to manage critically ill patients on mechanical ventilation. As a result, the sudden need to rapidly increase production has emphasized the need for adaptability for API CDMOs in maintaining drug supply, with some companies proving to be better prepared to withstand the pressures of quick scale-up than others. Growing demand for new therapies worldwide and an increase in the conduction of clinical research in the post-pandemic period are expected to support the market in the coming years.

Active Pharmaceutical Ingredient CDMO Market Report Highlights:

  • The traditional active pharmaceutical ingredient segment dominated the market and accounted for the largest revenue share of 39.8% in 2022, due to the high adoption of traditional API in majority of pharmaceuticals
  • The innovative drugs segment held 73.7% of the revenue share in 2022. This is largely attributed to increasing FDA approvals for new molecular entities, and the increased focus on R&D by innovator API companies
  • The oncology segment led the market with the highest revenue share of 35.5% in 2022. This is due to the increasing demand for highly potent APIs for cancer therapy
  • The biotech segment is expected to grow at the fastest rate of 7.0% over the forecast period, owing to the high adoption of biopharmaceuticals in the treatment of chronic and infectious diseases
  • The clinical workflow segment is anticipated to witness the fastest CAGR of 7.3% over the forecast period. An increase in the number of clinical research studies supporting the demand for APIs is one of the key factors driving segment growth
  • In Asia Pacific, the market is expected to register the fastest CAGR of 9.1% over the forecast period. Due to the extreme growth in the number of pharmaceutical companies and contract manufacturing organizations in developing countries such as India and China, the region is likely to overtake Europe and North America in the near future

Table of Contents

Chapter 1. Active Pharmaceutical Ingredient CDMO Market: Methodology and Scope

  • 1.1. Market Segmentation And Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Product Segment
      • 1.1.1.2. Synthesis Segment
      • 1.1.1.3. Drug Segment
      • 1.1.1.4. Application segment
      • 1.1.1.5. Workflow segment
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Primary Sources
  • 1.11. List of Abbreviations

Chapter 2. Active Pharmaceutical Ingredient CDMO Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Products And Synthesis Snapshots
  • 2.3. Drug And Application Snapshot
  • 2.4. Workflow Snapshot
  • 2.5. Competitive Landscape Snapshot

Chapter 3. Active Pharmaceutical Ingredient CDMO Market: Variables, Trends, & Scope

  • 3.1. Market Segmentation And Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Increase in pharmaceutical R&D investment
    • 3.4.2. Rapid demand for generic drugs
    • 3.4.3. Patient expiration
    • 3.4.4. Expanding consumption of biopharmaceuticals
  • 3.5. Market Restraint Analysis
    • 3.5.1. Compliance issues while outsourcing
  • 3.6. Active Pharmaceutical Ingredient CDMO Market Analysis Tools
    • 3.6.1. Industry Analysis - Porter's Five Forces
      • 3.6.1.1. Supplier Power
      • 3.6.1.2. Buyer Power
      • 3.6.1.3. Substitution Threat
      • 3.6.1.4. Threat Of New Entrant
      • 3.6.1.5. Competitive Rivalry
    • 3.6.2. PESTLE Analysis
      • 3.6.2.1. Political Landscape
      • 3.6.2.2. Technological Landscape
      • 3.6.2.3. Economic Landscape

Chapter 4. Active Pharmaceutical Ingredient CDMO Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Active Pharmaceutical Ingredient CDMO Market, Product Outlook
  • 4.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following:
    • 4.4.1. Traditional Active Pharmaceutical Ingredient (Traditional API)
      • 4.4.1.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 4.4.2. Highly Potent Active Pharmaceutical Ingredient (HP-API)
      • 4.4.2.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 4.4.3. Antibody Drug Conjugate (ADC)
      • 4.4.3.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)

Chapter 5. Active Pharmaceutical Ingredient CDMO Market: Synthesis Estimates & Trend Analysis

  • 5.1. Synthesis Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Active Pharmaceutical Ingredient CDMO Market, Synthesis Outlook
  • 5.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following:
    • 5.4.1. Synthetic
      • 5.4.1.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 5.4.2. Biotech
      • 5.4.2.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)

Chapter 6. Active Pharmaceutical Ingredient CDMO Market: Drug Estimates & Trend Analysis

  • 6.1. Drug Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Active Pharmaceutical Ingredient CDMO Market, Drug Outlook
  • 6.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following:
    • 6.4.1. Innovative
      • 6.4.1.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 6.4.2. Generics
      • 6.4.2.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)

Chapter 7. Active Pharmaceutical Ingredient CDMO Market: Application Estimates & Trend Analysis

  • 7.1. Application Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global Active Pharmaceutical Ingredient CDMO Market, Application Outlook
  • 7.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following:
    • 7.4.1. Oncology
      • 7.4.1.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 7.4.2. Hormonal
      • 7.4.2.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 7.4.3. Glaucoma
      • 7.4.3.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 7.4.4. Cardiovascular Disease
      • 7.4.4.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 7.4.5. Diabetes
      • 7.4.5.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 7.4.6. Others
      • 7.4.6.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)

Chapter 8. Active Pharmaceutical Ingredient CDMO Market: Workflow Estimates & Trend Analysis

  • 8.1. Workflow Market Share, 2023 & 2030
  • 8.2. Segment Dashboard
  • 8.3. Global Active Pharmaceutical Ingredient CDMO Market, Workflow Outlook
  • 8.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following:
    • 8.4.1. Clinical
      • 8.4.1.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 8.4.2. Commercial
      • 8.4.2.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)

Chapter 9. Active Pharmaceutical Ingredient CDMO Market: Regional Business Analysis

  • 9.1. Regional Market Share Analysis, 2023 & 2030
  • 9.2. Regional Market Dashboard
  • 9.3. Global Regional Market Snapshot
  • 9.4. Marker Size, & Forecasts Trend Analysis, 2018 To 2030:
  • 9.5. North America
    • 9.5.1. U.S.
      • 9.5.1.1. Key Country Dynamics
      • 9.5.1.2. Competitive Scenario
      • 9.5.1.3. Regulatory Framework
      • 9.5.1.4. U.S. Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.5.2. Canada
      • 9.5.2.1. Key Country Dynamics
      • 9.5.2.2. Competitive Scenario
      • 9.5.2.3. Regulatory Framework
      • 9.5.2.4. Canada Market Estimates And Forecasts 2018 - 2030 (USD Million)
  • 9.6. Europe
    • 9.6.1. UK
      • 9.6.1.1. Key Country Dynamics
      • 9.6.1.2. Competitive Scenario
      • 9.6.1.3. Regulatory Framework
      • 9.6.1.4. UK Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.6.2. Germany
      • 9.6.2.1. Key Country Dynamics
      • 9.6.2.2. Competitive Scenario
      • 9.6.2.3. Regulatory Framework
      • 9.6.2.4. Germany Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.6.3. Spain
      • 9.6.3.1. Key Country Dynamics
      • 9.6.3.2. Competitive Scenario
      • 9.6.3.3. Regulatory Framework
      • 9.6.3.4. Spain Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.6.4. France
      • 9.6.4.1. Key Country Dynamics
      • 9.6.4.2. Competitive Scenario
      • 9.6.4.3. Regulatory Framework
      • 9.6.4.4. France Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.6.5. Italy
      • 9.6.5.1. Key Country Dynamics
      • 9.6.5.2. Competitive Scenario
      • 9.6.5.3. Regulatory Framework
      • 9.6.5.4. Italy Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.6.6. Denmark
      • 9.6.6.1. Key Country Dynamics
      • 9.6.6.2. Competitive Scenario
      • 9.6.6.3. Regulatory Framework
      • 9.6.6.4. Denmark Market Estimates And Forecasts 2018 - 2030 (USD Million)
      • 9.6.6.5.
    • 9.6.7. Sweden
      • 9.6.7.1. Key Country Dynamics
      • 9.6.7.2. Competitive Scenario
      • 9.6.7.3. Regulatory Framework
      • 9.6.7.4. Sweden Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.6.8. Norway
      • 9.6.8.1. Key Country Dynamics
      • 9.6.8.2. Competitive Scenario
      • 9.6.8.3. Regulatory Framework
      • 9.6.8.4. Norway Market Estimates And Forecasts 2018 - 2030 (USD Million)
  • 9.7. Asia Pacific
    • 9.7.1. Japan
      • 9.7.1.1. Key Country Dynamics
      • 9.7.1.2. Competitive Scenario
      • 9.7.1.3. Regulatory Framework
      • 9.7.1.4. Japan Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.7.2. China
      • 9.7.2.1. Key Country Dynamics
      • 9.7.2.2. Competitive Scenario
      • 9.7.2.3. Regulatory Framework
      • 9.7.2.4. China Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.7.3. India
      • 9.7.3.1. Key Country Dynamics
      • 9.7.3.2. Competitive Scenario
      • 9.7.3.3. Regulatory Framework
      • 9.7.3.4. India Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.7.4. South Korea
      • 9.7.4.1. Key Country Dynamics
      • 9.7.4.2. Competitive Scenario
      • 9.7.4.3. Regulatory Framework
      • 9.7.4.4. South Korea Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.7.5. Thailand
      • 9.7.5.1. Key Country Dynamics
      • 9.7.5.2. Competitive Scenario
      • 9.7.5.3. Regulatory Framework
      • 9.7.5.4. Thailand Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.7.6. Australia
      • 9.7.6.1. Key Country Dynamics
      • 9.7.6.2. Competitive Scenario
      • 9.7.6.3. Regulatory Framework
      • 9.7.6.4. Australia Market Estimates And Forecasts 2018 - 2030 (USD Million)
  • 9.8. Latin America
    • 9.8.1. Brazil
      • 9.8.1.1. Key Country Dynamics
      • 9.8.1.2. Competitive Scenario
      • 9.8.1.3. Regulatory Framework
      • 9.8.1.4. Brazil Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.8.2. Mexico
      • 9.8.2.1. Key Country Dynamics
      • 9.8.2.2. Competitive Scenario
      • 9.8.2.3. Regulatory Framework
      • 9.8.2.4. Mexico Active Pharmaceutical Ingredient CDMO Market, 2018 - 2030 (USD Million)
    • 9.8.3. Argentina
      • 9.8.3.1. Key Country Dynamics
      • 9.8.3.2. Competitive Scenario
      • 9.8.3.3. Regulatory Framework
      • 9.8.3.4. Argentina Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.8.4. Colombia
      • 9.8.4.1. Key Country Dynamics
      • 9.8.4.2. Competitive Scenario
      • 9.8.4.3. Regulatory Framework
      • 9.8.4.4. Colombia Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.8.5. Chile
      • 9.8.5.1. Key Country Dynamics
      • 9.8.5.2. Competitive Scenario
      • 9.8.5.3. Regulatory Framework
      • 9.8.5.4. Chile Market Estimates And Forecasts 2018 - 2030 (USD Million)
  • 9.9. MEA
    • 9.9.1. South Africa
      • 9.9.1.1. Key Country Dynamics
      • 9.9.1.2. Competitive Scenario
      • 9.9.1.3. Regulatory Framework
      • 9.9.1.4. South Africa Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.9.2. Saudi Arabia
      • 9.9.2.1. Key Country Dynamics
      • 9.9.2.2. Competitive Scenario
      • 9.9.2.3. Regulatory Framework
      • 9.9.2.4. Saudi Arabia Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.9.3. UAE
      • 9.9.3.1. Key Country Dynamics
      • 9.9.3.2. Competitive Scenario
      • 9.9.3.3. Regulatory Framework
      • 9.9.3.4. UAE Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.9.4. Kuwait
      • 9.9.4.1. Key Country Dynamics
      • 9.9.4.2. Competitive Scenario
      • 9.9.4.3. Regulatory Framework
      • 9.9.4.4. Kuwait Market Estimates And Forecasts 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 10.2. Company /Competition Categorization
  • 10.3. Vendor Landscape
    • 10.3.1. List Of Key Distributors And Channel Partners
    • 10.3.2. Key Customers
    • 10.3.3. Key Company Market Share Analysis, 2023
    • 10.3.4. Cambrex Corporation
      • 10.3.4.1. Overview
      • 10.3.4.2. Financial Performance
      • 10.3.4.3. Product Benchmarking
      • 10.3.4.4. Strategic Initiatives
    • 10.3.5. Recipharm CP
      • 10.3.5.1. Overview
      • 10.3.5.2. Financial Performance
      • 10.3.5.3. Product Benchmarking
      • 10.3.5.4. Strategic Initiatives
    • 10.3.6. Thermo Fisher Scientific Inc. (Pantheon)
      • 10.3.6.1. Overview
      • 10.3.6.2. Financial Performance
      • 10.3.6.3. Product Benchmarking
      • 10.3.6.4. Strategic Initiatives
    • 10.3.7. CordenPharma International
      • 10.3.7.1. Overview
      • 10.3.7.2. Financial Performance
      • 10.3.7.3. Product Benchmarking
      • 10.3.7.4. Strategic Initiatives
    • 10.3.8. Samsung Biologics
      • 10.3.8.1. Overview
      • 10.3.8.2. Financial Performance
      • 10.3.8.3. Product Benchmarking
      • 10.3.8.4. Strategic Initiatives
    • 10.3.9. Lonza
      • 10.3.9.1. Overview
      • 10.3.9.2. Financial Performance
      • 10.3.9.3. Product Benchmarking
      • 10.3.9.4. Strategic Initiatives
    • 10.3.10. Catalent, Inc.
      • 10.3.10.1. Overview
      • 10.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 10.3.10.3. Product Benchmarking
      • 10.3.10.4. Strategic Initiatives
    • 10.3.11. Siegfried Holding AG
      • 10.3.11.1. Overview
      • 10.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 10.3.11.3. Product Benchmarking
      • 10.3.11.4. Strategic Initiatives
    • 10.3.12. Piramal Pharma Solutions
      • 10.3.12.1. Overview
      • 10.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 10.3.12.3. Product Benchmarking
      • 10.3.12.4. Strategic Initiatives
    • 10.3.13. Boehringer Ingelheim International GmbH
      • 10.3.13.1. Overview
      • 10.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 10.3.13.3. Product Benchmarking
      • 10.3.13.4. Strategic Initiatives
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제